Dyslipidemia
Report: Dyslipidemia drug-treated population to grow 4% annually
Published in Obesity and Diabetes Week, September 27th, 2004
Primary factors driving the rise in drug treatment in this population include increasing awareness of its coronary heart disease risk coupled with the availability of low-cost, generic statin substitutes to treat these patients.
The new Pharmacor study entitled "Dyslipidemia" also finds that Pfizer and Merck plan to fight back against generic erosion of atorvastatin and simvastatin, two leading statins.
"The launch of Pfizer's atorvastatin/torcetrapib and atorvastatin/amlodipine, and of Merck/Schering-Plough's...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Insulin Resistance
Insulin resistance and the endothelium reviewed - Obesity and Diabetes
Cellular approach to prevent insulin resistance through exercise presented - Obesity and Diabetes
Family of Acrp30/adiponectin structural and functional paralogs reviewed - Obesity and Diabetes
Glucose uptake reduction by peroxynitrite concurrent with receptor nitration - Obesity and Diabetes
Insulin resistance correlated with visceral fat to skeletal muscle ratio - Anorexia Nervosa
Predictors of leptin in adolescent girls with anorexia identified - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
